作者:Hernandez-Olmos, Victor、Heering, Jan、Marinescu, Beatrice、Schermeng, Tina、Ivanov, Vladimir V.、Moroz, Yurii S.、Nevermann, Sheila、Mathes, Marius、Ehrler, Johanna H. M.、Alnouri, Mohamad Wessam、Wolf, Markus、Haydo, Alicia S.、Schmachtel, Tessa、Zaliani, Andrea、Höfner, Georg、Kaiser, Astrid、Schubert-Zsilavecz, Manfred、Beck-Sickinger, Annette G.、Offermanns, Stefan、Gribbon, Philipp、Rieger, Michael A.、Merk, Daniel、Sisignano, Marco、Steinhilber, Dieter、Proschak, Ewgenij
DOI:10.1021/acs.jmedchem.3c02164
日期:——
for the development of new therapeutics in neuropathic pain, acute myeloid leukemia, and inflammation. However, there is still a lack of potent, selective, and drug-like G2A agonists to be used as a chemical tool or as the starting matter for the development of drugs. In this work, we present the discovery and structure–activity relationship elucidation of a new potent and selective G2A agonist scaffold
G 蛋白偶联受体 G2A 被认为是开发神经性疼痛、急性髓性白血病和炎症新疗法的有希望的靶点。然而,仍然缺乏有效的、选择性的、类药物的G2A激动剂来用作化学工具或作为药物开发的起始物质。在这项工作中,我们展示了一种新的有效、选择性 G2A 激动剂支架的发现和结构-活性关系阐明。系统优化导致 (3-(吡啶-3-基甲氧基)苯甲酰基) -d-苯丙氨酸 (T-10418) 表现出比参考和天然配体 9-HODE 更高的效力,并且在 G 蛋白偶联受体中具有高选择性。凭借其良好的活性、清晰的选择性、优异的溶解度和高代谢稳定性,T-10418 有资格作为研究 G2A 激活效应的药理学工具。